Physicians are a privileged group entrusted with an unshrouded view ofour patients' minds and bodies and the relatively autonomous capabilityof prescribing various managements, medicines, and procedures. For example, patients often willingly accept our recommendation for choiceof competing treatments based on their confidence in our medical opinion.This profound trust is granted to us by society because of an educationgained in part by their generosity (as tax payers, benefactors, and trainingsubjects during our learning curve) and thus requires a high level of responsibilityto prescribe management choices that are intrinsically best for each individualpatient without regard to our own financial interest.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.